Anxiety in Schizophrenia:Treatment with Pregabalin by Schjerning, Ole
 
  
 
Aalborg Universitet
Anxiety in Schizophrenia
Treatment with Pregabalin
Schjerning, Ole
DOI (link to publication from Publisher):
10.5278/vbn.phd.med.00111
Publication date:
2018
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Schjerning, O. (2018). Anxiety in Schizophrenia: Treatment with Pregabalin. Aalborg Universitetsforlag. Aalborg
Universitet. Det Sundhedsvidenskabelige Fakultet. Ph.D.-Serien https://doi.org/10.5278/vbn.phd.med.00111
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: December 27, 2020
O
LE SC
H
JER
N
IN
G
A
N
XIETY IN
 SC
H
IZO
PH
R
EN
IA
ANXIETY IN SCHIZOPHRENIA
TREATMENT WITH PREGABALIN
BY
OLE SCHJERNING
DISSERTATION SUBMITTED 2018
 
 
 
ANXIETY IN SCHIZOPHRENIA 
TREATMENT WITH PREGABALIN 
by 
Ole Schjerning 
 
Dissertation submitted 2018 
  
Dissertation submitted: March 2018
PhD supervisor:  Associate professor, MD, Ph.D. 
   Klaus Damgaard Jakobsen
   Aalborg University Hospital, 
   Department of Psychiatry.
   Aalborg University,
   Department of Clinical Medicine.
   Aalborg, Denmark
Assistant PhD supervisor: Professor, MD, Ph.D.
   Per Damkier
   Odense University Hospital,
   Clinical Biochemistry and Pharmacology.
   University of Southern Denmark,
   Institute of Clinical Research.
   Odense, Denmark
PhD committee:  Professor, MD Jørgen Aagaard (chairman)
   Aalborg University Hospital
   Associate Professor, MD, Ph.D. Bjørn H. Ebdrup
   Copenhagen University Hospital
   Associate professor, MD, Ph.D. Jonas Eberhard
   Lund University
PhD Series: Faculty of Medicine, Aalborg University
Department: Department of Health Science and Technology 
ISSN (online): 2246-1302
ISBN (online): 978-87-7210-094-4
Published by:
Aalborg University Press
Langagervej 2
DK – 9220 Aalborg Ø
Phone: +45 99407140
aauf@forlag.aau.dk
forlag.aau.dk
© Copyright: Ole Schjerning
Printed in Denmark by Rosendahls, 2018
v 
ENGLISH SUMMARY 
 
Background 
Anxiety symptoms is common among patients with schizophrenia and pose a large 
negative impact on patients perceived quality of life, daily functioning and is 
associated with increased risk of suicide. 
The evidence concerning the pharmacological treatment of anxiety in schizophrenia 
is sparse and rely primarily on treatment guidelines aimed at non-psychotic anxiety 
disorders. The anxiolytic properties of pregabalin is well established. Based on case 
reports and smaller case series pregabalin has been suggested as treatment for 
anxiety in schizophrenia. However, no randomized clinical trials have been 
conducted to investigate the efficacy of pregabalin in patients with schizophrenia 
and severe anxiety symptoms. 
Increasing numbers of clinical CNS trials fail to separate active drug from placebo. 
Methodological and statistical problems related to study design and methods of 
efficacy assessment may be a part of the explanation. Centralized rating in 
psychometric testing has been suggested as a method to increase accuracy and 
reduce bias and focus on the psychometric properties of the assessment scales may 
increase the precision in clinical trials. 
Although the pharmacokinetics of pregabalin limits the risk of drug-drug-
interactions, case reports have suggested an interaction between pregabalin and the 
antipsychotic drug clozapine. The mechanism behind this possible interaction 
remains unknown and has not been investigated systematically. Although, 
pregabalin is considered well tolerated, case reports and epidemiological studies 
have suggested an abuse potential of pregabalin, especially among persons with a 
history of substance abuse. Both the potential DDI with clozapine and the abuse 
potential may limit the use of pregabalin for the treatment of anxiety in 
schizophrenia. 
 
Methods 
The main study of this thesis (the PACS study) is a randomized double-blinded 
placebo-controlled trial designed to evaluate the efficacy and safety of pregabalin as 
add-on treatment for anxiety in patients with schizophrenia by using remote 
centralized ratings of the Hamilton Anxiety Scale (HAM-A) as primary outcome 
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(Study I). By using HAM-A ratings from both site-based ratings and remote 
centralized ratings the validity and scalability of HAM-A14 and HAM-A6 and 
differences in efficacy estimations was evaluated. Further, “exit-poll” data were 
used to evaluate the blinding success in the PACS study (Study II). Blood samples, 
from a subsample of participants in antipsychotic treatment with clozapine, was used 
to assess the stability of plasma clozapine during concomitant treatment with 
pregabalin (Study III). A systematic literature search and review of preclinical, 
clinical and epidemiological data was commenced to evaluate the abuse potential of 
pregabalin (Study IV). 
Overall findings 
Pregabalin showed superiority to placebo in reducing anxiety symptom severity as 
measured by the HAM-A6. Superiority could not be confirmed on the HAM-A14. 
Pregabalin was generally well tolerated. Analysis of the statistical properties of the 
HAM-A14 and the HAM-A6 showed a sufficient scalability of the HAM-A6 whereas 
the the HAM-A14 showed signs of multidimensionality. The suspected DDI between 
pregabalin and clozapine could not be confirmed in the analyses of the blood 
material from the PACS study. Overall, the available literature suggests an 
important clinical abuse potential of pregabalin and this may be a limitation in the 
use of pregabalin for the treatment of anxiety in patients with schizophrenia – 
especially in patients with ongoing or previous substance abuse. 
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DANSK RESUME 
 
Baggrund 
Angst forekommer hyppigt hos personer med skizofreni. Tilstedeværelsen af 
angstsymptomer har en negativ indvirkning på den oplevede livskvalitet, dagligt 
funktionsniveau og er forbundet med en øget risiko for selvmord. 
Den videnskabelige evidens for farmakologisk behandling af angst ved skizofreni er 
sparsom og baserer sig primært på guidelines vedrørende behandling af egentlige 
angstlidelser. Den angstdæmpende effekt af pregabalin er velkendt og pregabalin har 
på baggrund af kasuistikker været foreslået som behandling af angst hos personer 
med skizofreni. Indtil videre har der ikke været gennemført større randomiserede 
kliniske studier med det formål at undersøge effekten af pregabalin til behandling af 
angst ved skizofreni.  
Gennem de seneste år har et stigende antal kliniske studier fejlet i forhold til at 
kunne påvise effekt af aktive lægemidler i sammenligning med placebo. 
Metodologiske og statistiske problemstillinger i forbindelse med designet af 
studierne menes at være en medvirkende årsag hertil. Brug af centraliseret rating er 
blevet foreslået som en mulighed i forhold til at håndtere nogle af de førnævnte 
problemstillinger. 
En mulig interaktion mellem pregabalin og det antipsykotiske lægemiddel clozapin 
har været beskrevet i enkelte kasuistikker. Stigende plasmakoncentration af clozapin 
er observeret efter opstart af samtidig behandling med pregabalin. Det biologiske 
grundlag for denne mulige interaktion er ikke klarlagt. Yderligere har 
epidemiologiske studier og flere publicerede kasuistikker peget på et muligt 
misbrugspotentiale ved pregabalin. Begge disse forhold kan potentielt begrænse 
brugen af pregabalin som effektiv og sikker behandling af patienter med skizofreni 
og betydende angstsymptomer. 
 
Metode 
Hovedstudiet i denne afhandling undersøger effekten af pregabalin, sammenlignet 
med placebo, i en gruppe af personer med skizofreni og betydende angstsymptomer 
(Studie I). På baggrund af data fra centraliseret rating og site-baseret rating 
undersøges de psykometriske egenskaber af HAM-A14 og HAM-A6, samt forskelle i 
effektmålinger baseret på de forskellige rating-metoder (Studie II). På baggrund af 
blodprøve-materiale indsamlet i Studie I undersøges stabiliteten af plasma-clozapin 
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under samtidig behandling med pregabalin (Studie III). I en systematisk 
gennemgang af publiceret litteratur gives en vurdering af misbrugspotentialet ved 
pregabalin ud fra prækliniske, kliniske og epidemiologiske data (Studie IV). 
 
Overordnede resultater 
Samlet set blev der fundet effekt af pregabalin ved behandling af angst hos patienter 
med skizofreni, målt på HAM-A6 skalaen, samt på den psykiske angstfaktor af 
HAM-A14 skalaen. Forskellen mellem placebo og pregabalin var statistisk betydende 
og effektstørrelsen var moderat. Behandlingen var generelt veltålt. Analyse af 
HAM-A data viste en større psykometrisk validitet af HAM-A6, sammenlignet med 
HAM-A14. Mistanken om en lægemiddelinteraktion mellem pregabalin og clozapin 
kunne ikke bekræftes ud fra analyserne af det indsamlede blodprøve materiale. I 
litteraturgennemgangen blev der fundet indicier for et betydende misbrugspotentiale 
af pregabalin. Dette kan potentielt være en begrænsende faktor i forhold til 
anvendelsen af pregabalin til behandling af angst ved skizofreni. 
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1. BACKGROUND 
 
ANXIETY IN SCHIZOPHRENIA 
Schizophrenia is a severe, often chronic mental disorder affecting approximately 
0.5% of the population, with up to 10 % of patients being institutionalized (5). The 
psychopathology of schizophrenia includes psychotic symptoms, e.g. hallucinations 
and delusions, negative symptoms, e.g. blunted affect and social withdrawal, 
disorganization of thoughts and behavior and cognitive impairment (6).  
Anxiety is a future-oriented emotional state that is experienced by all humans to 
varying degree (7). Anxiety is accompanied by a characteristic set of behavioral and 
physiological responses, experienced as anxiety symptoms, including avoidance, 
vigilance and arousal, which evolved to protect the individual from danger (8). 
Anxiety symptoms are conceptualized as anxiety disorders (ADs) when they 
constitute specified syndromes and are intensive, recurrent, and impede an 
individual’s psychosocial functioning (9). 
Anxiety symptoms have long been recognized as a core aspect of schizophrenia 
(10). However, the diagnostic approach and classification of anxiety in 
schizophrenia is inconsistent. In the categorical approach to diagnosing psychiatric 
illnesses in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition 
(DSM-IV), anxiety in schizophrenia is diagnosed as comorbid anxiety disorders and 
not perceived as a core symptom set in schizophrenia (11). It is estimated that up to 
40% of patients fulfils the criteria for any anxiety disorders (12), with lifetime 
prevalence being as high as 70% (13). 
In the World Health Organization International Classification of Disease, 10th 
edition (WHO ICD-10), anxiety symptoms in patients with schizophrenia is not 
diagnosed, as the ICD-10 system uses a hierarchical approach and disorders lower 
in the diagnostic hierarchy is not added as comorbidities to the main diagnosis, e.g. 
schizophrenia. The downside to this approach may be that anxiety symptoms 
receives less attention than e.g. positive symptoms as clinicians might pay more 
attention to hallucinations and delusions than the more unspecific anxiety 
symptoms (14). 
The level of anxiety symptoms may not be constant throughout the course of 
schizophrenia, but rather fluctuating with other symptoms (15). Some studies have 
found that the severity of acute psychosis is positively correlated with the severity 
of anxiety symptoms and severity of depressive symptoms. The clinical attention 
towards the psychotic symptoms may overshadow the presence and importance of 
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anxiety or depressive symptoms (16). Among patients in post-acute or stable phase 
of their disorder, severe levels of anxiety in schizophrenia are linked with greater 
levels of hallucinations, poorer psychosocial functioning lesser hope for the future 
(17). In a 12-month study examining patients hospitalized due to psychotic relapse, 
a general lessening of symptoms and a decrease in anxiety symptoms occurred over 
time, but comorbid anxiety disorder was still present in 47% of patients and 33% 
fulfilled criteria for more than one anxiety disorder after the psychotic episode had 
diminished (18).  
Anxiety results in increased burden and poorer prognosis of the disease and is 
associated with increased risk of suicide and sleeping disturbances, and anxiety 
symptoms are highly associated with quality of life in patients with schizophrenia 
(19). However, little research has been conducted to address the treatment of 
anxiety symptoms in this population and clinicians mostly rely on the guidelines for 
treatment of anxiety disorders in non-psychotic populations. 
 
TREATMENT OF ANXIETY IN SCHIZOPHRENIA 
The treatment of anxiety disorders in non-psychotic populations has been well 
investigated and thorough treatment guidelines exists (20, 21). The most widely 
used drugs are the selective serotonin and noradrenaline reuptake inhibitors (SSRI 
and SNRI), certain tricyclic antidepressants (TCA), benzodiazepines (BZD) and 
anticonvulsants, like pregabalin (20). The use of atypical antipsychotics, either as 
monotherapy or as augmenting therapy have been investigated in clinical trials with 
promising results, however, the side effects profile may limit the use in the 
treatment of anxiety disorders (22). 
Antipsychotic drugs remain a cornerstone in the treatment of schizophrenia. The 
specific effect of antipsychotic drugs on anxiety symptoms, have only been 
investigated in few studies, mostly case reports or smaller studies with open design 
(23-25). The evidence does not allow for any clear recommendations so far.  
Another reasonable approach is the use of drugs with known anxiolytic effect as 
add-on or augmenting treatment. However, the evidence remains sparse and the 
treatment is often leading to unwanted and potentially unsafe polypharmacy (26, 
27). As reviewed by Temmingh & Stein (28) and Howells, Kingdon & Baldwin 
(29), evidence for the use of known anxiolytics is mostly based on existing 
treatment guidelines for anxiety disorders. A few randomized studies have focused 
on the use of SSRIs, SNRIs or TCAs for the treatment of anxiety disorders in 
schizophrenia, mostly concerning the treatment of Obsessive-Compulsive Disorder 
(OCD) or Obsessive-Compulsive Symptoms (OCS) (30-32). 
 
21 
 
The anxiolytic effect of BZDs is well-established, and this class of drugs is 
commonly used as concomitant treatment for patients with schizophrenia (33). 
Although, BZDs may be acceptable in the treatment of acute anxiety states (34), 
long-term use is not recommended due to adverse effects, i.e. reduced cognitive 
functioning and risk of tolerance and dependence (35). Further, the use of BZDs is 
associated with a marked increase in mortality in patients with schizophrenia (36, 
37). 
Different novel drugs with known or potential anxiolytic effect have been suggested 
in the treatment of anxiety in schizophrenia, among these pregabalin (29, 38).  
 
PREGABALIN 
Pregabalin is an alkylated analogue of γ-aminobutyric acid (GABA) and binds to 
the α2d type 1 protein of the P/Q voltage-dependent calcium channel and reduces 
the central release of excitatory molecules (39, 40). Pregabalin has been shown 
effective in the treatment of GAD (41, 42) with effect size comparable to 
Lorazepam and Venlafaxine (43), but with a more rapid onset of action than 
venlafaxine and a more favorable cognitive profile compared to BZDs (44). 
Further, pregabalin has been suggested as treatment of alcohol and BZD 
dependence (45), both conditions which occur commonly in patients with 
schizophrenia (46). 
Based on case reports and smaller case series, pregabalin has been suggested as “off 
label” add-on treatment for anxiety in schizophrenia (47, 48). In some cases, 
treatment with pregabalin resulted in a reduction of both anxiety symptoms, 
positive and negative symptoms and enabled a reduction in the use of 
benzodiazepines (48). However, the evidence for the use of pregabalin in the 
treatment of anxiety in schizophrenia remain sparse and no randomized studies 
have been conducted so far.  
The dose range of pregabalin is 150-600 mg per day, given in either two or three 
divided doses. In healthy volunteers, pregabalin is rapidly and well absorbed with 
peak plasma concentrations occurring 1.3 hours (h) after oral administration and 
with an absolute bioavailability of approximately 90% (49). Pregabalin does not 
bind to plasma proteins. The apparent volume of distribution following oral 
administration is approximately 0.5 L/kg.  
Metabolism of pregabalin is negligible as most of the drug is excreted unchanged in 
the urine with a mean elimination half-life of 6.3 h in subjects with normal renal 
function. Pregabalin plasma clearance is directly proportional to creatinine 
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clearance, but independent of sex, race, age, female hormonal status, daily dose and 
dosing regimen (49, 50). Dosage reduction should be considered in patients with 
impaired renal function (50). 
Although, treatment with pregabalin generally is considered well tolerated, the use 
of pregabalin for the treatment of anxiety in schizophrenia may be problematic. 
Pregabalin added to clozapine treatment has been associated with increases in 
plasma levels of clozapine (51-53). Clozapine may cause several dose dependent 
side-effects such as dizziness, constipation and seizures (54) and several serious 
drug-drug interactions involving clozapine have been described, with some of them 
being potentially fatal (55, 56). The mechanism for the potential pharmacokinetic 
interaction between pregabalin and clozapine remains unclear and a biological 
plausible explanation has not been found. 
Abuse and misuse of pregabalin has been described in case reports and 
epidemiologic studies (57-59), and the European Summary of Product 
characteristics (SPC) holds a specific warning on the abuse potential of pregabalin 
(60). The abuse potential of pregabalin could be a limiting factor for the use of 
pregabalin in patients with schizophrenia. 
 
ASSESSMENT OF ANXIETY IN SCHIZOPHRENIA 
Accurate assessment and diagnosing of anxiety in schizophrenia is challenging. 
Anxiety symptoms may be a pathophysiological consequence of medical conditions 
like endocrine disorders, cardio-pulmonary disorders or related to substance abuse 
(9). Adverse effects from ongiong psychopharmacological treatment, e.g. akathisia, 
may mimic somatic manifestations of anxiety (28, 61). Thorough investigation of 
medical history, physical examination, blood testing and electrocardiography may 
be nescessary in the differential diagnosing of anxiety symptoms.  
When assessing anxiety severity in schizophrenia it is important to consider the 
overlap between positive and negative symptoms, symptoms of depression and the 
stage of the illness (acute psychosis or chronic stage). Severity of depressive 
symptoms can be evaluated with the Calgary Depression Scale for Schizophrenia 
(CDSS) (62). This scale is especially developed for assessing depression in 
schizophrenia and a comparison to the Hamilton Depression Scale (HAM-D) found 
the CDSS to be less confounded by positive and negative symptoms (63). 
The Positive and Negative Syndrome Scale (PANSS) (64) is one of the most widely 
used assessment scales for measuring positive and negative symptoms of 
schizophrenia (65). PANSS is a clinician administered scale, based on a structured 
clinical interview. The full scale consists of 30 items, each item is scored on a 7-
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point scale with increasing severity of psychopathology, “1” equals symptom 
absent and “7” symptom being extreme, thus the theoretical range is 30 to 210 (64). 
The composite scale consists of three subscales (positive symptoms, negative 
symptoms and general psychopathology) based on the hypothesis that positive and 
negative symptoms constitute the main dimensions of schizophrenia (66, 67). The 
psychometric properties and clinical validity of the two-factor model in the PANSS 
scale has been questioned and other factor models have been suggested (65, 68, 69). 
In the five-factor model suggested by Lindenmayer et al (70), Factor 5 covers the 
dimension of Anxiety/Depression based on four items from the general 
psychopathology subscale, anxiety (G2), guilt (G3), tension (G4) and depression 
(G6). 
Whether anxiety in schizophrenia differ qualitatively from conventional anxiety 
disorders remains unclear (11). However, anxiety in schizophrenia may possess 
specific features, as being more silent and intense compared to anxiety disorders or 
anxiety in mood disorders, it may be accompanied by psychomotor disturbances 
such as agitation and it has less somatic impact (71). A novel composite rating scale 
(SAES), using items from both the PANSS scale, the Brief Psychiatric Rating Scale 
(BPRS) and the Hamilton Anxiety Rating Scale (HAM-A) has been developed and 
validated in patients with schizophrenia (71), but the SAES needs further evaluation 
in clinical trials regarding the psychometric properties. Until further research has 
been conducted, the use of assessment scales designed for other conditions must be 
used. 
  
THE HAMILTON ANXIETY SCALE 
The Hamilton Anxiety Rating Scale (HAM-A) (72) is one of the most widely used 
rating scales to assess severity of anxiety symptoms. It was originally developed to 
assess symptom severity in anxiety neurosis but have been used in other psychiatric 
conditions as well. The HAM-A has been used in clinical studies for the assessment 
of anxiety in schizophrenia and found to have acceptable level of internal 
consistency (73). 
In placebo-controlled, randomized clinical trials to evaluate the anxiolytic effect of 
medication the HAM-A (72) remains the most widely used outcome measure. The 
HAM-A is clinician administered, typically based on a semi-structured interview. 
The original scale, developed in 1959 by Max Hamilton, contained 13 items (74). 
Later the scale was expanded to 14 items (72), which is now the predominant 
version of the scale. The individual items are scored on a 5-point scale (0 = “not 
present” to 4 = “maximum degree”) given the full HAM-A14 a theoretical range 
from 0 to 56. The HAM-A has a high interrater reliability, even with less 
experienced raters (75). The items of the HAM-A14 is presented in Table 1. 
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By factor analysis, Hamilton confirmed multidimensionality of the HAM-A14 by 
identifying to factors, a psychic anxiety factor (items 1 to 6 and item 14) and a 
somatic anxiety factor (items 7 to 13) (72). The usefulness of these two factors for 
discriminating between differential treatment responses has been shown in 
randomized clinical trial investigating the efficacy of different anxiolytic drugs. 
Over the past decades, the antidepressants have been shown to be superior to 
benzodiazepines, e.g. diazepam, in placebo-controlled trials with the HAM-A. 
Thus, one of the first (76) demonstrated that imipramine was significantly superior 
to diazepam especially on the psychic anxiety factor in the HAM-A. The SSRIs 
showed superiority to placebo on the psychic factor of the HAM-A (77, 78). As a 
primary anxiolytic drug pregabalin was approved in the treatment of generalized 
anxiety disorder by demonstrating significant superiority over placebo and 
benzodiazepines on the psychic factor of the HAM-A (79). 
 
Table 1 – HAM-A14 (*items included in the HAM-A6) (adapted from 
Gjerris et al (75)). 
Item number Symptom 
1* Anxious mood 
2* Tension 
3* Fears 
4 Insomnia 
5* Difficulties in concentration and memory 
6 Depressed mood 
7* General somatic symptoms (Muscular tension) 
8 General somatic symptoms (sensory) 
9 Cardiovascular symptoms 
10 Respiratory symptoms 
11 Gastrointestinal symptoms 
12 Genito-urinary symptoms 
13 Other autonomic symptoms 
14* Behavior during interview 
  
 
A shorter version of the scale, HAM-A6, including the items of anxious mood, 
tension, fears, difficulty in concentration, muscular tension, and anxious behavior 
during interview (items 1, 2, 3, 5, 7 and 14), has been found to cover the core items 
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for anxiety state severity in GAD (80). Bech (43) re-analyzed placebo-controlled 
pregabalin trials in GAD using the HAM-A6 and confirmed that pregabalin was 
superior to placebo on the HAM-A6 (43). 
 
METHODOLOGICAL ISSUES IN EFFICACY TRIALS INVOLVING 
PSYCHOTROPICS 
In the recent years, a growing number of trials have failed to show difference 
between active treatment and placebo (81, 82). This observation may partly be 
attributed to an apparent increase in placebo response over the years (83). Several 
factors may be responsible for this change and for example increased clinical 
attention during study visits may contribute (83). Another issue is the use of 
quantitative psychometric testing for inclusion criteria and outcome assessment 
resulting in inflated baseline values, a phenomenon known as the therapeutic 
contrast effect or “baseline inflation”, where raters might tend to give a too high 
score at baseline to ensure that the patient fulfils the inclusion criteria (83). Placebo 
group regress towards “true values” resulting in a falsely high placebo response. 
Another challenge related to the use of psychometric rating scales is the 
psychometric and statistical properties of the scales. To perform sufficiently a 
psychometric scale must be uni-dimensional, meaning that responses to individual 
items are explained by a common latent trait, i.e. anxiety. Further, individual items 
must be locally independent meaning that the relationship between items are 
explained by the latent trait and not by response to other items. The monotonicity of 
a scale means that the responses to a given item is a non-decreasing function of the 
latent trait. The Mokken Scale Analysis (MSA) is a method of testing whether a 
scale fulfills these assumptions (84). 
Concealment of treatment allocation and maintaining blinding is essential to the 
validity of clinical trials. However, concurrent rating of both effect parameters and 
adverse effects may cause functional un-blinding of assessors (85). Use of 
centralized rating has been suggested as a method of complying with some of the 
problems concerning the use of psychometric testing in order to make more precise 
ratings in efficacy studies (86). Different setups and methods have been described 
in previous studies, i.e. use of video conferencing or teleconferencing making 
ratings in real time (87, 88).  
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CENTRALIZED RATING OF THE HAMILTON ANXIETY SCALE 
The high inter-rater reliability of the HAM-A has contributed to the widely use as 
outcome measure in trials investigating the anxiolytic effect of drugs (89). 
However, Shen et al (88) have introduced the use of remote centralized raters to 
take into account some of the constant errors related to the site-based raters which 
are in operation in the traditional clinical trials, such as the therapeutic contrast 
effect (90, 91). This constant error is not covered by the evaluation of the inter-rater 
reliability. 
The remote centralized raters are blinded to the order of the assessment visits in the 
study and to the protocol. They have only access to the video-recorded interviews 
with the participating patients (88). It is the site-based raters who are responsible for 
the management of the study performing all the protocol-related clinical 
assessments. The knowledge of typical adverse effects or assessment number may 
result in functional un-blinding of site-based raters and thereby biasing the 
assessments. Because Shen et al (88) demonstrated that patients with schizophrenia 
are willing and able to participate in clinical trials using remote centralized raters 
with access to video-taped interviews, remote centralized rating was used as a 
precautionary method of blinding in the PACS-study. 
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2. AIMS 
STUDY I (PACS STUDY) 
The aims of this study were to evaluate the efficacy, tolerability and safety of 
pregabalin as add-on treatment for anxiety in patients with schizophrenia. The study 
was conducted as a randomized, placebo-controlled, double-blinded clinical trial. 
The HAM-A was used to quantify severity of anxiety symptoms and to measure 
treatment response. Outcome measures were assessed at baseline, after 4 weeks and 
after 8 weeks of treatment. 
 
STUDY II 
The aim for this study was to describe the method of remote centralized ratings 
used in the PACS Study. The scalability and statistical properties of the HAM-A14 
and the HAM-A6 was analyzed using data from both the centralized ratings and 
site-based ratings. Differences in efficacy assessments between the different 
methods of rating was also assessed.  
 
STUDY III 
The aim for this study was to explore the stability of plasma clozapine 
concentrations before and after initiation of pregabalin in patients in antipsychotic 
treatment with clozapine. This study was conducted as a prospective observational 
study based on blood samples obtained from the PACS Study. 
 
STUDY IV 
The aim for this study was to evaluate the abuse potential of pregabalin through a 
systematic review of preclinical, clinical and epidemiologic studies. 
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3. METHODS 
STUDY I (PACS STUDY) 
The PACS study was an investigator-initiated study designed as a randomized, 
double-blinded, placebo-controlled study. Patients were recruited from all five 
regions of Denmark. First patient was included at 5th of March 2012 and last patient 
ended the study at 15th of August 2016 (1). The study was ended before sample size 
goal was met due to failure in accessing eligible patients (1). The methods used in 
Study I (PACS study) is described in detail in the appended Paper I (1). 
 
PARTICIPANTS 
In- and exclusion criteria for Study I is described in detail in the appended Paper I 
(1). A brief overview is provided below: 
Inclusion criteria: 
• Age 18 to 65 years. 
• Diagnosis of schizophrenia1 (ICD-10 F20.0 to F20.3 or F20.9). 
• No changes in primary psychopharmacologic treatment (antipsychotics, 
antidepressants and sedatives) for at least 4 weeks. 
• HAM-A14 > 15 (site-based ratings). 
• PANSS total score < 70. 
• CDSS score < 10. 
Exclusion criteria: 
• Significant substance abuse. 
• Dysregulated diabetes. 
• For Females - pregnancy or breastfeeding.  
• Legal coercion according to the Danish mental health act. 
• Suicidal ideation.  
                                                        
1 Schizophrenia diagnoses were verified by the investigator, either by review of psychiatric 
charts or by systematic diagnostic interviews.  
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RANDOMIZATION AND STUDY INTERVENTIONS 
Patients were randomized 1:1 to either pregabalin or placebo. A flexible dosage 
regime was used – with dosages between 150 mg/d and 600 mg/d depending on 
patient’s subjective anxiolytic effect and experience of adverse effects (1). Details 
concerning study interventions and the procedures of randomization and 
concealment of study medication is described in further details in the appended 
Paper I (1). 
 
PRIMARY AND SECONDARY OUTCOMES 
Primary outcome was change in anxiety symptom severity as measured by the 
HAM-A (1). Efficacy outcome was based on the centralized ratings and assessed as 
the difference between baseline ratings and ratings after 4 and 8 weeks of treatment 
(1). Analyses were made for the full HAM-A14 scale, the HAM-A6 and the psychic 
and somatic anxiety factor of the HAM-A14 (1). Procedures for centralized rating is 
described in greater detail in the appended Paper II (2). Secondary outcomes of 
Study I is described in detail in the appended Paper I (1) and a brief overview of 
the ratings scales used is provided below: 
Psychopathology: 
• Positive and Negative Syndrome Scale (PANSS) (64) 
• Clinical Global Impression – Severity Scale (CGI-S) (92) 
• Clinical Global Impression - Improvement Scale (CGI-I) (92) 
Quality of life: 
• WHO Quality of Life instrument (WHOQOL-BREF) (93).  
Quality of sleep: 
• Leeds Sleep Evaluation Questionnaire (LSEQ) (94) 
Functioning: 
• Personal and Social Performance Scale (PSP) (95). 
Tolerability: 
• Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale (96) 
Sedation: 
• Visual Analog Scale (VAS) 
Akathisia: 
• Barnes Akathisia Rating Scale (BARS) (97) 
Cognitive functioning: 
• Brief Assessment of Cognition in Schizophrenia (BACS) (98). 
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STUDY II 
 
HAM-A INTERVIEWS AND PROCEDURES OF CENTRALIZED RATING 
This study was based on the HAM-A interviews performed under the PACS study 
(Study I). Both remote centralized ratings and site-based ratings were analyzed. 
Comparisons were made between the two methods of rating in respect to baseline 
values and differences in efficacy outcomes (2). A detailed description of the 
procedures concerning HAM-A interviews and the remote centralized ratings are 
presented in the appended Paper II (2). 
 
ASSESSMENT OF BLINDING 
End-of-trial questions to both study participants and site-based raters about what 
treatment they thought the participant had been allocated to was used in the 
assessment of blinding success (2). Bang’s Blinding Index (BI) (99) were calculated 
for both study participants and site-based raters. The method used for assessment of 
blinding success in the PACS study is described in detail in the appended Paper II 
(2). 
 
THE MOKKEN SCALE ANALYSIS 
The non-parametric item response theory model developed by Mokken (84) was 
used to assess the scalability of the HAM-A14 and the HAM-A6. According to this 
model the coefficient of homogeneity is considered as an expression of the extent to 
which the individual items in the scale can be rank-ordered by their locations on the 
underlying dimension of anxiety severity (100). Data from the centralized ratings 
was used (2). A detailed description of the Mokken scale analysis is provided in the 
appended Paper II (2). 
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STUDY III  
 
STUDY DESIGN AND PARTICIPANTS 
The stability of plasma clozapine during concomitant treatment with pregabalin was 
evaluated in an observational prospective study design using blood material from 
the PACS study. Of the total 54 participants in the PACS study, 23 received 
treatment with clozapine. Blood samples from baseline and at least one of the 
following two assessments were available for 15 patients. Eight had been allocated 
to treatment with pregabalin and 7 to placebo (3). 
 
SAMPLE HANDLING AND LABORATORY ANALYSIS 
The procedures of sample handling and laboratory analyses performed in Study III 
is described in detail in the appended Paper III (3). Blood samples were drawn in 
the morning and before any morning dosage of clozapine. Participants were 
instructed to be fasting and not to smoke or drink caffeine containing beverages 
before blood samples were obtained. Full blood samples were frozen at -80°C until 
batch analysis. Analyses of plasma clozapine concentration were performed on the 
9th of May 2017. 
 
 
STUDY IV 
 
LITERATURE SEARCH 
Study IV was conducted as a systematic review of preclinical, clinical and 
epidemiological studies concerning pregabalin. Pubmed, Embase and the websites 
of the European Medicines Agency (EMA) and the American Food and Drug 
Administration (FDA) were searched using the search term “pregabalin”. The 
search strategy and selection processes are described in detail in the appended 
Paper IV (4).  
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4. STATISTICAL METHODS 
SAMPLE SIZE ESTIMATION 
The details of sample size estimation in Study I is described in Paper I (1): 
“Power calculation was made using STATA 11 Corp. The assumptions were that 
mean baseline HAM-A14 was 23 ± 9. A clinically relevant change was a 5-point 
improvement and mean endpoint HAM-A14 was 18 ± 6. With these assumptions, a 
power of 80% would require 25 patients in each treatment group. A sample size of 
35 in each treatment group was chosen to keep sufficient power with a drop-out 
rate of up to 30%.” 
 
DATA HANDLING 
The procedures for data handling in the PACS study is described in detail in Paper 
I (1): 
“All data collected in the PACS study was entered in EPI-data using double entry 
by two different persons. Entry-files were compared electronically to avoid typing 
errors. Statistical analyses were performed in STATA version 14 (StataCorp. 2015. 
Stata Statistical software: Release 14. College Station, Texas, USA). Primary 
analysis was Intention-To-Treat (ITT) and secondarily as per protocol (PP). 
Missing data in the ITT-analysis was replaced as “Last Observation Carried 
Forward” (LOCF) and all participants receiving at least one dose of treatment 
medication was included in the ITT analysis. In the PP analysis, patients with a 
compliance <70% were excluded and missing data was not replaced.” 
 
STATISTICAL ANALYSES 
Mean (integer) values of ratings from all three raters were used in the statistical 
analyses on the HAM-A data from centralized ratings. The statistical methods used 
in the PACS study is described in Paper I (1): 
“Data were assessed for normality using visual inspection. Logarithmic 
transformation was used when possible for variables not normally distributed. 
When transformation was not possible or not sufficient, data was tested with the 
Wilcoxon rank sum test. Effect size was estimated as Cohen’s d. For the main 
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analysis, mean differences and corresponding confidence intervals were estimated; 
the corresponding p-values were calculated using two-sided independent samples t-
tests. Comparison of categorical data was made using the Fishers’ Exact test. For 
explorative analyses (specific adverse reactions) and explorative comparisons 
where estimates of differences could not be computed, we adopted a Bonferroni 
corrected significance level of < 0.001.” 
In Study II, interrater agreement for the three centralized raters was estimated as 
intra-class correlation coefficients using a two-way fixed effects model measuring 
absolute agreement on average scores (ICC (3, k), absolute) (2). In the Mokken 
Scale Analysis, Loevingers coefficient of homogeneity was calculated for the HAM-
A14 and the HAM-A6 on ITT data from both the centralized ratings and the site-
based ratings (2). All statistical analyses in were made in STATA version 14 
(StataCorp. 2015. Stata Statistical software: Release 14. College Station, Texas, 
USA). Add-on software packages was used for the calculations of Loevingers 
coefficient of homogeneity and Bangs Blinding Index (101). 
In Study III, change in plasma clozapine between baseline and each of the 
following assessments were calculated for each treatment group (3). Hypothesis 
testing on baseline concentration and concentration after 4 and 8 weeks of treatment 
were made using the Wilcoxon signed-rank test (3). 
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5. ETHICAL CONSIDERATIONS 
The PACS study were performed in accordance with the ICH-CGP guidelines and 
the Declaration of Helsinki (1). All participants gave their informed written consent 
to participation (1). Participants consent to the video recording and use of HAM-A 
interviews in the centralized rating procedures (2) and the collection of blood 
material for later analyses were given separately (3). The Local Ethics Committee, 
the Danish Health Authority and the Danish Data Protection Agency approved the 
PACS study protocol (1). The collection of blood material for analysis of plasma 
levels of clozapine was approved by the Danish Health Authority, Danish Data 
Protection Agency and the Local Ethics Committee as an amendment to the original 
PACS study protocol (3).  
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6. RESULTS 
STUDY I 
PARTICIPANTS FLOW 
A CONSORT diagram of participants flow through Study I is shown in Figure 1 
(Originally presented as Figure 1 in Paper I) (1). 
 
Figure 1 – CONSORT Diagram 
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BASELINE DATA 
Baseline demographics and clinical characteristics for each treatment group are 
summarized in Table 2 and Table 3 (originally presented as Table 1 in Paper I) (1).  
 
OUTCOMES AND ESTIMATION 
Outcomes and estimations of the Intention-to-treat analyses of the HAM-A data is 
originally presented in Paper I (1). An overview of the results is shown in Table 4 
(originally presented as Table 2 in Paper I) (1). No substantial differences were 
seen in the ITT analyses compared to the PP analyses (1). Secondary outcomes of 
the PACS study are originally presented in Paper I (1) and data is presented in 
summary in Table 5 (originally Table 3 in Paper I) (1). Some patients showed 
inability to withstand the full test program of the PACS study. As a result, the 
numbers analyzed for secondary parameters vary. Baseline LSEQ was missing or 
incomplete for 7 patients. Baseline BACS was missing for 1 patient. Data from 
these patients are not included in neither ITT or per protocol analyses. 
 
ADVERSE EVENTS 
Adverse effects occurring during the PACS study are originally presented in Paper 
I (1). Data from the UKU ratings are summarized in Table 6 (originally presented 
as Table 4 in Paper I) (1). Only patients with at least one follow-up assessment 
were included in the analysis. In total, UKU data for 47 patients (17 females and 30 
males) were included in the assessment of adverse effects (1). A further 
presentation of data on change in body weight and adverse effects not covered by 
the UKU scale is presented in the appended Paper I (1). 
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Table 2 – Baseline demographics and clinical characteristics 
 Placebo 
group (n=26) 
Pregabalin 
group 
(n=28) 
Variable Mean SD Mean SD 
- Age (years) 43 10 38 12 
- Body weight (kg)  91.7 17.4 84.0 18.9 
- Height (cm) 175 10.8 175 10.4 
- Systolic blood pressure (mmHg)  123.5 11.2 122.3 10.2 
- Diastolic blood pressure (mmHg)  81.8 7.2 81.1 7.0 
Laboratory test results     
- P-Creatinine (µmol/l) 83.9 11.8 81.4 12.4 
- QTc (ms)  426.8 29.0 423.5 25.6 
- Heart rate (min-1)  74.3 20.2 81.4 19.0 
Psychometrics     
- CDSS (total score) 
 
3.8 2.7 4.3 2.6 
Variable N % N % 
Sex     
- Male 19 73 17 61 
- Female 7 27 11 39 
Schizophrenia subtype     
- Paranoid (F20.0) 22 85 22 78 
- Undifferentiated (F20.3) - - 3 11 
- Unspecified (F20.9) 4 15 3 11 
Housing situation     
- Independent 18 69 19 68 
- Institutionalized 7 27 9 32 
- Hospitalized 1 4 - - 
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Table 3 – Treatment characteristics. (*Dosage per injection was divided by the number of days 
between each injection.) 
 
 
Placebo group (n=26) Pregabalin group (n=28) 
Treatment 
characteristics N 
Mean daily dosage 
(mg) N 
Mean daily dosage 
(mg) 
Oral Antipsychotics 
- Clozapine 10 379 13 425 
- Olanzapine 6 24.2 2 20 
- Quetiapine 5 395 6 491.7 
- Chlorprothixen 2 165 2 25 
- Amisulpride 1 300 2 550 
- Risperidone - - 2 2.5 
- Aripiprazole 4 17.5 7 21.4 
- Paliperidone 1 150 - - 
- Sertindole 1 16 - - 
LAI Antipsychotics* 
- Olanzapine 1 28.9 - - 
- Flupentixole - - 1 7.1 
- Risperidone 1 2.7 3 3.3 
- Paliperidone 1 5.4 1 6.3 
- Aripiprazole 1 14.3 3 14.0 
Hypnotics 
- Clonazepam 4 1.95 3 0.83 
- Oxazepam 2 22.5 1 15 
- Alprazolam 1 0.3 - - 
- Zopiclone 4 7.5 2 5.65 
- Zolpidem 2 10 - - 
- Hydroxyzine - - 1 50 
- Promethazine 1 25 - - 
Antidepressants 
- Amitriptyline 1 125 - - 
- Fluoxetine 1 20 - - 
- Citalopram 3 33.3 3 33.3 
- Paroxetine 1 40 - - 
- Sertraline 6 112.5 5 120 
- Escitalopram 1 20 3 20 
- Mirtazapine 1 30 2 37.5 
- Venlafaxine 1 225 2 187.5 
 
 
 
 
 
 
41 
 
 
Ta
bl
e 
4 
- N
um
be
rs
 a
na
ly
ze
d:
 p
la
ce
bo
, n
=2
6 
an
d 
pr
eg
ab
al
in
, n
=2
8.
 C
om
pa
ri
so
ns
 m
ad
e 
w
ith
 tw
o-
sa
m
pl
e 
in
de
pe
nd
en
t t
-te
st
s. 
 
Th
eo
re
tic
al
 ra
ng
e 
fo
r H
A
M
-A
14
 to
ta
l (
0 
to
 5
6)
, H
A
M
-A
6 
(0
 to
 2
4)
 a
nd
 H
A
M
-A
 (p
sy
ch
ic
 a
nd
 so
m
at
ic
 fa
ct
or
s)
 (0
 to
 3
2)
. 
      
     
Sc
or
e 
at
 B
as
el
in
e 
C
ha
ng
e 
af
te
r 
8 
w
ee
ks
 o
f t
re
at
m
en
t 
 
P
la
ce
bo
 
P
re
ga
ba
lin
 
P
la
ce
bo
 
P
re
ga
ba
lin
 
D
if
fe
re
nc
e 
be
tw
ee
n 
gr
ou
ps
 
 
 
 
M
ea
n 
SD
 
M
ea
n 
SD
 
M
ea
n 
95
%
 C
I 
M
ea
n 
95
%
 C
I 
M
ea
n 
95
%
 C
I 
E
ff
ec
t s
iz
e 
P
 
H
A
M
-A
14
 
 
22
.2
 
5.
9 
22
.4
 
4.
7 
- 
3.
4 
-5
.1
 to
 -
1.
7 
-6
 
-8
.9
 to
 -
3.
0 
2.
6 
-0
.8
 to
 5
.9
 
0.
42
 
0.
13
 
H
A
M
-A
6 
 
10
.6
 
2.
8 
10
.8
 
2.
0 
-1
.0
 
-2
.2
 to
 0
.1
 
-3
.3
 
-4
.7
 to
 -
2.
0 
2.
3 
0.
6 
to
 4
.0
 
0.
72
 
0.
01
 
P
sy
ch
ic
 fa
ct
or
 
12
.8
 
3.
3 
13
.0
 
3.
0 
-1
.6
 
-3
.0
 to
 -
0.
2 
-4
.1
 
-6
.0
 to
 -
2.
1 
2.
5 
0.
1 
to
 4
.9
 
0.
57
 
0.
04
 
So
m
at
ic
 fa
ct
or
 
 
9.
5 
3.
8 
9.
5 
3.
1 
-1
.8
 
-2
.9
 to
 -
0.
7 
-2
.1
 
-3
.5
 to
 -
0.
7 
0.
3 
-1
.5
 to
 2
.0
 
0.
08
 
0.
76
 
ANXIETY IN SCHIZOPHRENIA 
42 
 
 
Ta
bl
e 
5 
- S
ec
on
da
ry
 o
ut
co
m
e 
m
ea
su
re
s.
 I
nt
en
tio
n-
To
-T
re
at
 a
na
ly
se
s.
 N
um
be
rs
 a
na
ly
ze
d;
 1 (
Pl
ac
eb
o 
n=
26
, p
re
ga
ba
lin
 n
=2
8)
, 2
(p
la
ce
bo
 n
=2
5,
 p
re
ga
ba
lin
 n
=2
8)
, 
 3 (
Pl
ac
eb
o 
n=
22
, p
re
ga
ba
lin
 n
=2
7)
, 4
(p
la
ce
bo
 n
=2
1,
 p
re
ga
ba
lin
 n
=2
6)
.  
 
V
al
ue
 a
t b
as
el
in
e 
C
ha
ng
e 
af
te
r 
8 
w
ee
ks
 o
f t
re
at
m
en
t 
 
P
la
ce
bo
 
P
re
ga
ba
lin
 
P
la
ce
bo
 
P
re
ga
ba
lin
 
D
if
fe
re
nc
e 
be
tw
ee
n 
gr
ou
ps
 
O
ut
co
m
e 
va
ri
ab
le
 
M
ea
n 
SD
 
M
ea
n 
SD
 
M
ea
n 
95
%
 C
I 
M
ea
n 
95
%
 C
I 
M
ea
n 
95
%
 C
I 
P
 
P
A
N
SS
 T
ot
al
1  
57
.2
 
8.
7 
56
.8
 
6.
8 
-1
.2
 
-3
.5
 to
 1
.1
 
-5
.0
 
-8
.3
 to
 -1
.7
 
3.
8 
-0
.1
 to
 7
.7
 
0.
05
 
P
A
N
SS
 P
os
iti
ve
1  
14
.0
 
3.
2 
14
.5
 
3.
6 
0 
-1
.0
 to
 1
.1
 
-0
.6
4 
-1
.9
 to
 0
.6
 
0.
7 
-0
.9
 to
 2
.3
 
0.
47
 
P
A
N
SS
 N
eg
at
iv
e1
 
13
.0
 
4.
3 
13
.4
 
4.
8 
0 
-1
.0
 to
 1
.0
 
-1
.0
 
-2
.4
 to
 0
.4
 
1.
0 
-0
.7
 to
 2
.7
 
0.
24
 
P
A
N
SS
 G
en
er
al
1  
30
.2
 
4.
4 
28
.9
 
3.
5 
-1
.2
 
-2
.4
 to
 0
 
-3
.4
 
-5
.6
 to
 -1
.2
 
2.
1 
-0
.3
 to
 4
.6
 
0.
07
 
P
A
N
SS
 A
nx
ie
ty
/D
ep
re
ss
io
n1
 
12
.8
 
2.
2 
12
.5
 
2.
4 
-1
.0
 
-1
.8
 to
 -0
.3
 
-2
.7
 
-4
.2
 to
 -1
.2
 
1.
7 
0 
to
 3
.3
 
0.
05
 
B
A
C
S 
co
m
po
si
te
 s
co
re
2  
32
.7
 
8.
5 
32
.9
 
6.
4 
2.
5 
0.
8 
to
 4
.3
 
-0
.2
 
-2
.2
 to
 1
.8
 
2.
8 
0.
1 
to
 5
.4
 
0.
1 
V
A
S 
Se
da
tio
n3
 
56
.3
 
20
.0
 
52
.6
 
23
.5
 
-3
 
-1
2.
9 
to
 7
 
1.
7 
-8
.4
 to
 1
1.
9 
4.
7 
-9
.3
 to
 1
8.
7 
0.
5 
W
H
O
-Q
O
L 
– 
O
ve
ra
ll 
Q
O
L3
 
44
.3
 
17
.6
 
43
.5
 
20
.3
 
6.
3 
1.
0 
to
 1
1.
6 
12
 
4.
0 
to
 2
0.
1 
5.
7 
3.
7 
to
 1
5.
2 
0.
22
 
W
H
O
-Q
O
L 
– 
P
hy
si
ca
l H
ea
lth
3  
58
 
15
.9
 
50
.5
 
13
.1
 
1 
-4
.6
 to
 5
.9
 
10
 
6.
3 
to
 1
3.
6 
9 
3.
3 
to
 1
5.
4 
<0
.0
1 
W
H
O
-Q
O
L 
– 
P
sy
ch
ol
og
ic
al
3  
37
.6
 
15
.9
 
35
.2
 
14
.3
 
6 
1.
2 
to
 9
.8
 
13
 
5.
5 
to
 1
9.
6 
7 
1.
1 
to
 1
5.
1 
0.
09
 
W
H
O
-Q
O
L 
– 
E
nv
ir
on
m
en
t3  
51
.7
 
13
.3
 
54
.2
 
16
.5
 
-1
 
-5
 to
 3
 
0 
-4
 to
 4
 
1 
-4
 to
 7
 
0.
68
 
 
P
la
ce
bo
 
P
re
ga
ba
lin
 
P
la
ce
bo
 
P
re
ga
ba
lin
 
D
if
fe
re
nc
e 
be
tw
ee
n 
gr
ou
ps
 
O
ut
co
m
e 
va
ria
bl
e 
M
ed
ia
n 
IQ
R
 
M
ed
ia
n 
IQ
R
 
M
ed
ia
n 
IQ
R
 
M
ed
ia
n 
IQ
R
 
M
ed
ia
n 
P 
W
H
O
-Q
O
L 
– 
So
c.
 r
el
at
io
ns
hi
ps
3  
64
.5
 
50
 to
 7
2 
56
 
50
 to
 6
6 
0 
-8
 to
 6
 
6 
-2
 to
 1
0 
6 
0.
20
 
LS
E
Q
 –
 G
et
tin
g-
to
-s
le
ep
4  
15
4 
13
4 
to
 1
81
 
15
0 
12
0 
to
 1
57
 
-2
 
-3
3 
to
 1
9 
13
 
0 
to
 3
9 
15
 
0.
01
 
LS
E
Q
 –
 Q
ua
lit
y-
of
-s
le
ep
4  
99
 
74
 to
 1
18
 
86
 
69
 to
 1
00
 
1 
-7
 to
 2
0 
6 
0 
to
 4
8 
5 
0.
06
 
LS
E
Q
 –
 A
F
S4
 
10
0 
75
 to
 1
02
 
10
0 
56
 to
 1
29
 
0 
-9
 to
 1
4 
0 
-3
5 
to
 1
9 
0 
0.
97
 
LS
E
Q
 –
 B
F
W
4  
13
3 
10
3 
to
 1
52
 
13
2 
76
 to
 1
59
 
4 
-1
1 
to
 3
0 
0 
-2
4 
to
 4
5 
4 
0.
68
 
C
G
I-
S1
 
4 
4 
to
 5
 
4 
4 
to
 5
 
0 
0 
to
 0
 
0 
0 
to
 0
 
0 
0.
51
 
P
SP
2  
47
 
38
 to
 4
9 
47
 
44
 to
 5
0 
0 
-3
 to
 3
 
-1
 
-3
 to
 4
 
1 
0.
79
 
B
A
R
S 
To
ta
l1  
2 
0 
to
 2
 
1 
0 
to
 3
 
0 
0 
to
 0
 
0 
-2
 to
 0
 
0 
0.
43
 
B
A
R
S 
G
lo
ba
l A
ss
es
sm
en
t1  
1 
0 
to
 1
 
1 
0 
to
 2
 
0 
0 
to
 0
 
0 
-1
 to
 0
 
0 
0.
46
 
 
 
43 
 
Table 4 - Total number of patients included in analysis of adverse effects based on the UKU scale: 
47 1Females (n=17), 2Males (n=30) 
 Total Placebo Pregabalin Fisher’s exact 
 N % N % N % P 
Concentration difficulties 7 15 3 14 4 16 >0.99 
Increased fatigability 15 32 6 27 9 36 0.55 
Sedation 9 19 4 18 5 20 >0.99 
Failing memory 11 23 5 23 6 24 >0.99 
Depression 14 30 9 41 5 20 0.20 
Tension 8 17 4 18 4 16 >0.99 
Increased duration of sleep 17 36 2 9 15 60 0.001 
Reduced duration of sleep 5 11 3 14 2 8 0.65 
Increased dream activity 9 19 3 14 6 24 0.47 
Emotional indifference 6 13 2 9 4 16 0.67 
Dystonia 2 4 0 0 2 8 0.49 
Rigidity 3 6 0 0 3 12 0.24 
Hypokinesia / Akinesia 3 6 0 0 3 12 0.24 
Hyperkinesia 6 13 1 5 5 20 0.19 
Tremor 6 13 3 14 3 12 >0.99 
Akathisia 10 21 3 14 7 28 0.30 
Epileptic seizures 2 4 0 0 2 8 0.49 
Paresthesia 5 11 2 9 3 12 >0.99 
Accommodation disturbances 6 13 1 5 5 20 0.19 
Increased salivation 7 15 2 9 5 20 0.42 
Dryness of mouth 9 19 5 23 4 16 0.72 
Nausea / Vomiting 11 23 6 27 5 20 0.73 
Diarrhea 10 21 4 18 6 24 0.73 
Constipation 6 13 3 14 3 12 >0.99 
Micturition Disturbances 9 19 4 18 5 20 >0.99 
Polyuria / Polydipsia 11 23 2 9 9 36 0.04 
Orthostatic dizziness 13 28 7 32 6 24 0.75 
Palpitations / Tachycardia 9 19 4 18 5 20 >0.99 
Increased tendency to sweating 3 6 1 5 2 8 >0.99 
Rash 4 9 1 5 3 12 0.61 
Pruritus 3 6 1 5 2 8 >0.99 
Photosensitivity 3 6 0 0 3 12 0.24 
Increased pigmentation 4 9 0 0 4 16 0.11 
Weight gain 22 47 6 27 16 64 0.02 
Weight loss 10 21 7 32 3 12 0.15 
Menorrhagia1 5 29 2 33 3 27 >0.99 
Amenorrhea1 6 35 1 17 5 46 0.33 
Galactorrhea1 4 24 2 33 2 18 0.58 
Gynecomastia2 1 3 0 0 1 7 0.47 
Increased sexual desire 2 4 0 0 2 8 0.49 
Diminished sexual desire 8 17 2 9 6 24 0.25 
Erectile dysfunction2 6 20 2 13 4 29 0.38 
Ejaculatory dysfunction2 5 17 1 6 4 29 0.16 
Orgasmic dysfunction 10 21 3 14 7 28 0.30 
Dry vagina1 2 12 0 0 2 18 0.52 
Headache 12 26 6 27 6 24 >0.99 
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STUDY II 
CENTRALIZED RATINGS 
A total of 149 HAM-A interviews were available for centralized rating and the 
rating procedures started on July 1st, 2016 and ended September 30th, 2016 (2). 
 
BLINDING OUTCOMES 
Data from the analysis of blinding success is presented in Table 7 (originally 
presented as Table 1 in Paper II) (2).  
 
Table 5 - Assessment of blinding success. 
 Study participants’ Answer, No.  
Intervention Pregabalin Placebo Do Not Know Total Data missing 
Pregabalin 14 8 2 24 4 
Placebo 13 12 0 25 1 
Total 27 20 2 49 5 
Bangs Blinding index: 
Study participants allocated to pregabalin:  0.25 (95% CI -0.06 to 0.56) 
Study participants allocated to placebo:      -0.04 (95% CI -0.37 to 0.29) 
 
 Site-based raters’ Answer, No.  
Intervention Pregabalin Placebo Do Not Know Total Data missing 
Pregabalin 13 10 1 24 4 
Placebo 4 18 1 23 3 
Total 17 28 2 47 7 
Bangs Blinding index: 
Study participants allocated to pregabalin:  0.13 (95% CI -0.2 to 0.45) 
Study participants allocated to placebo:       0.61 (95% CI 0.35 to 0.87) 
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DIFFERENCES IN RATINGS – SITE-BASED VERSUS CENTRALIZED 
RATINGS 
Mean ratings over time for each treatment group is presented graphically in Figure 
2 (originally presented as Figure 1 in Paper II) (2) and differences in baseline 
values and effect sizes after 8 weeks of treatment is presented in Table 8 (originally 
presented as Table 2 in Paper II) (2). A further description of the differences seen 
between site-based and remote centralized ratings is presented in the appended 
Paper II (2). 
 
INTERRATER AGREEMENT – CENTRALIZED RATERS 
ICC comparing ratings from all CR on individual items at the three different 
assessments are presented in Table 9 (originally presented as Table 3 in Paper II) 
(2). 
 
Figure 2 - Difference between site-based and centralized ratings of the HAM scale 
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Table 1 - Primary outcome measures. ITT analyses of centralized and site-based ratings. 
Rating scale and method Placebo 
 
Pregabalin 
 
Difference after 8 weeks 
 
 Mean (SD) Mean (SD) Mean (95% CI) Effect size P 
Centralized ratings: All originally included participants, ITT analyses (placebo n=26, pregabalin n=28). 
HAM-A14 22.2 (5.9) 22.4 (4.7) 2.6 (-0.8 to 5.9) 0.42 0.13 
HAM-A6 10.6 (2.8) 10.8 (2.0) 2.3 (0.6 to 4.0) 0.72 0.01 
HAM-A (Psychic factor) 12.8 (3.3) 13.0 (3.0) 2.5 (0.1 to 4.5) 0.57 0.04 
HAM-A (Somatic factor) 9.5 (3.8) 9.5 (3.1) 0.3 (-1.5 to 2.0) 0.08 0.77 
Centralized ratings: Baseline HAM-A14 ≤15 excluded, ITT analyses (placebo n=22, pregabalin n=25). 
HAM-A14 23.9 (4.6) 23.4 (3.7) 3.2 (-0.4 to 6.9) 0.50 0.08 
HAM-A6 11.4 (2.0) 10.2 (1.7) 2.2 (0.3 to 4.1) 0.69 0.02 
HAM-A (Psychic factor) 13.7 (2.4) 13.6 (2.4) 2.7 (0.0 to 5.3) 0.59 0.05 
HAM-A (Somatic factor) 10.4 (3.3) 9.9 (3.1) 0.3 (-1.7 to 2.3) 0.1 0.73 
Site-based ratings: All originally included participants, ITT analyses (placebo n=26, pregabalin n=28). 
HAM-A14 24.7 (4.8) 25.3 (4.8) 3.9 (0.3 to 7.4) 0.59 0.03 
HAM-A6 12.8 (2.0) 12.5 (2.2) 1.9 (-0.1 to 3.9) 0.53 0.06 
HAM-A (Psychic factor) 15.0 (2.6) 15.0 (3.0) 2.8 (0.3 to 5.3) 0.60 0.03 
HAM-A (Somatic factor) 9.6 (3.8) 10.3 (3.7) 1.0 (-1.0 to 3.0) 0.26 0.33 
 
Table 6 - ICC values. Interrater Agreement between individual central raters compared in a two-
way mixed effects model on absolute agreement.  
 Baseline ratings1 4 week ratings2 8 week ratings3 
HAM Item: ICC 95% CI ICC 95% CI ICC 95% CI 
Item 1 0.85 0.76 to 0.91 0.94 0.90 to 0.96 0.93 0.88 to 0.96 
Item 2 0.82 0.72 to 0.89 0.92 0.87 to 0.95 0.91 0.85 to 0.95 
Item 3 0.85 0.77 to 0.91 0.94 0.90 to 0.96 0.94 0.89 to 0.96 
Item 4 0.88 0.81 to 0.93 0.92 0.87 to 0.95 0.90 0.84 to 0.95 
Item 5 0.81 0.68 to 0.89 0.86 0.75 to 0.92 0.86 0.76 to 0.92 
Item 6 0.95 0.92 to 0.97 0.96 0.93 to 0.98 0.95 0.91 to 0.97 
Item 7 0.82 0.72 to 0.89 0.91 0.86 to 0.95 0.90 0.84 to 0.94 
Item 8 0.88 0.81 to 0.93 0.88 0.80 to 0.93 0.92 0.85 to 0.96 
Item 9 0.89 0.83 to 0.93 0.97 0.96 to 0.98 0.96 0.94 to 0.98 
Item 10 0.96 0.94 to 0.98 0.92 0.86 to 0.95 0.97 0.95 to 0.98 
Item 11 0.96 0.94 to 0.98 0.96 0.93 to 0.97 0.96 0.94 to 0.98 
Item 12 0.89 0.83 to 0.93 0.90 0.83 to 0.94 0.90 0.84 to 0.94 
Item 13 0.90 0.85 to 0.94 0.93 0.90 to 0.96 0.93 0.89 to 0.96 
Item 14 0.60 0.38 to 0.75 0.58 0.34 to 0.75 0.72 0.55 to 0.84 
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MOKKEN SCALE ANALYSIS 
The coefficients of homogeneity for HAM-A14 and HAM-A6 for both the 
centralized ratings and site-based ratings, are shown in Table 10 (originally 
presented as Table 2 in Paper II) (2).  
 
Table 7 – Coefficients of homogeneity. Analyses based 
on ITT data from 8 weeks assessment. 
 Coefficient of Homogeneity 
Method of rating HAM-A14 HAM-A6 
Centralized Rating 0.30 0.43 
Site-based Rating 0.28 0.37 
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STUDY III 
SAMPLE 
Baseline characteristics for patients included in Study III is presented in Table 11 
(originally presented as Table 1 in Paper III) (3). Median number of days from 
baseline assessment to initiation of pregabalin was 5, ranging from 1 to 13 days. 
Median number of days from initiation of pregabalin to the second assessment was 
27 days, ranging from 23 to 32 days, and to the third assessment 56 days, ranging 
from 51 to 61 days. Further details are provided in the appended Paper III (3). 
 
Table 8 - Clinical and treatment characteristics at baseline. 
Variable Placebo group (N=7) Pregabalin group (N=8) 
 N % N % 
Male sex 5 71 4 50 
Smokers 3 43 8 100 
 Median Min - Max Median Min - Max 
Age (years) 50 43 to 52 42 22 to 58 
BMI (kg/m2) 32.5 28.1 to 35.9 27.4 21.1 to 43.5 
Plasma creatinine (µmol/L) 86 68 to 103 74 66 to 117 
Dosage of clozapine (mg/day) 400 225 to 700 425 150 to 500 
Dosage of pregabalin at 4 weeks’ assessment 
(mg/day) 600 150 to 600 450 450 to 600 
Dosage of pregabalin at 8 weeks’ assessment 
(mg/day) 600 450 to 600 600 450 to 600 
 
 
CHANGE IN PLASMA CLOZAPINE 
Baseline values and change in plasma clozapine from baseline to the assessments 
after 4 and 8 weeks of treatment are summarized in Table 12 (originally presented 
as Table 2 in Paper III) (3). The largest individual increase in plasma clozapine 
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from baseline to 4 weeks assessment was 15% in the pregabalin group and 22% in 
the placebo group. The largest individual increase from baseline to 8 weeks 
assessment was 6% in the pregabalin group and 64% in the placebo group. 
A graphical presentation of the individual variation in concentration to dose ratio 
(C/D) over time is shown in Figure 3 (originally presented as Figure 1 in Paper 
III) (3) and boxplots for the assessments in each treatment group is shown in 
Figure 4 (Originally presented as Figure 2 in Paper III) (3). Further details of the 
change in p-clozapine is presented in the appended Paper III (3). 
 
Table 9 - Baseline p-clozapine and absolute change initiation of pregabalin. (1Hypothesis testing 
was made using the Wilcoxon signed-rank test.  
Treatment 
- Assessment N 
Median p-clozapine [ng/mL] 
(min – max) 
Median difference from baseline 
(min – max) 
Comparison to 
baseline1 
Placebo     
 - Baseline 7 497.8 (153.0 - 1059.8) - - 
 - 4 weeks 5 524.8 (138.1 - 765.2) 43.4 (-14.9 - 140.3) P=0.08 
 - 8 weeks 7 488.9 (191.0 - 1082.3) 26.9 (-36.0 - 397.4) P=0.18 
     
Pregabalin     
 - Baseline 8 516.5 (190.5 - 673.8) - - 
 - 4 weeks 8 501.3 (149.8 - 569.0) -29.9 (-179.2 - 72.7) P=0.09 
 - 8 weeks 6 467.4 (266.1 - 582.6) -102.3 (-236.2 - 14.0) P=0.12 
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Figure 3 -  Graphical presentation of p-clozapine (ng/mL) compared to dose (mg/day), over time 
 
 
Figure 4 - Box plots of plasma clozapine concentration at baseline and after 4 and 8 weeks of 
treatment with pregabalin. 
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STUDY IV 
RESULTS FROM LITERATURE SEARCH AND SELECTION PROCESS 
Literature search was performed on the 29th of November 2014 (4). No additional 
data was provided by the Marketing Authorization Holder (4). Selection tree from 
the literature search is shown in Figure 5 (Originally presented as Figure 1 in 
Paper IV) (4).  
 
Figure 5 – Selection tree from literature search. 
 
In total 17 preclinical studies were identified – which included seven unpublished 
studies presented in a FDA report, 102 clinical studies and 13 epidemiological 
studies. A total of 27 case reports were identified of which misuse and abuse related 
events were reported in 9 case reports – covering a total of 10 individual patients. 
The included studies and case reports are presented in brief overview in Table 1 to 
4 in the appended Paper IV (4). 
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7. DISCUSSION 
EFFICACY OF PREGABALIN FOR ANXIETY IN SCHIZOPHRENIA 
The main topic of this thesis is the evaluation of pregabalin in the treatment of 
anxiety in patients with schizophrenia. In the PACS study, pregabalin was 
compared to placebo in patients diagnosed with schizophrenia (1). 
Overall, a higher reduction in anxiety symptom severity was seen in the pregabalin 
group. However, when looking at the full HAM-A14 scale this difference was not 
statistically significant. In the analyses of the subscales of the HAM-A a clinically 
relevant and statistically significant difference between groups was seen on the 
HAM-A6. Studies on GAD have found the HAM-A6 to cover the core items of 
anxiety, namely the items of anxious mood, psychic tension, fears, intellectual 
disturbances, and anxious behavior observed at the interview (43, 80). 
Other clinical trials investigating the effect of pregabalin have found effect sizes 
comparable to those seen in the PACS study (43) and different drugs may have the 
ability to show effect either on the somatic factor or the psychic factor of the HAM-
A scale (102). 
Pregabalin is not known to possess antipsychotic effects and in fact, worsening of 
hallucinations have been associated with treatment of pregabalin (103). In the 
PACS study, three patients experienced deterioration of hallucinations – all three 
allocated to treatment with pregabalin (1). However, in a small case series 
investigating the effect of pregabalin in patients with schizophrenia, a reduction in 
positive symptom severity on the PANSS scale was found (48). The PANSS scale 
were used in the PACS study as a secondary efficacy outcome (1). Overall a larger 
reduction in total PANSS score was found in the pregabalin group. However, as 
seen in Table 5, the largest change was seen on items in the general symptoms 
subscale and no relevant change was found on the subscales of positive or negative 
symptoms (1). As a further evaluation was made using the “five-factor model” (70) 
which confirmed that the primary change in PANSS scores was on the items of 
anxiety specific symptoms (1). 
Overall quality of life is lower among persons with schizophrenia compared to the 
general population (104) and anxiety symptoms impose a negative impact on 
perceived quality of life (19). Overall quality of life for the participants in the 
PACS study were found to be comparable to the results founds in a Danish study 
concerning patients with schizophrenia (104). As seen in Table 5, changes in 
quality of life domains were in favor of pregabalin but only in the domain of 
“physical health” were the difference found to be statistically significant. The short 
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duration of the PACS study might not be sufficient to detect true changes in quality 
of life. 
Decreased functioning of sleep is a common symptom in anxiety disorders. In the 
PACS study, sleep functioning was evaluated using the patient rated LSEQ scale. 
The pregabalin group had a larger change towards better functioning in the 
“getting-to-sleep” domain and, although not statistically significant, in the 
“quality-of-sleep” domain (1). The differences seen between groups might be 
indicative of the anxiolytic effect of pregabalin but could as well be the result of 
adverse effects. Somnolence is a frequent adverse effect to pregabalin (105). 
However, on the VAS scale used for assessment of patient perceived sedation only 
a small change was seen for the pregabalin group. As presented in Table 6, a 
notable difference between groups were found in the “increased duration of sleep” 
whereas no relevant difference was found on the “sedation” item. Overall, the 
results indicate that the effect on sleep functioning is not only attributable to the 
sedative effects of pregabalin. 
 
TOLERABILITY OF PREGABALIN 
In the PACS study, overall drop-out rate was lower than expected (1). As shown in 
Figure 1, a total of three patients in the pregabalin group discontinued the study 
intervention due to suspected adverse effects. Corresponding number for the 
placebo group was two.  
Dizziness is a common adverse effect to treatment with pregabalin (105). Dizziness 
occurred more frequently in the pregabalin group but the difference between groups 
were not statistically significant (1). Weight gain, increased duration of sleep and 
polyuria/polydipsia were significantly also more reported by patients in the 
pregabalin group compared to the placebo group (1). Weight gain is a critical issue 
for many patients with schizophrenia and may negatively affect treatment 
adherence and is associated with lower quality of life (106). The findings in the 
UKU data was confirmed by the body weight measurements performed at each 
study visit (1). Eighty-six percent of patients in the pregabalin group experienced 
weight gain from baseline to end-trial assessment, with a mean weight gain of 2.6 
kg, corresponding numbers for the placebo group were 35% and a mean gain of 1.1 
kg (1). The findings in the PACS study concerning weight gain is comparable to 
those reported by Englisch et al. (48). Although definitions are not consistent in 
literature, a weight change of 7% from baseline weight is often considered as 
clinically significant (107, 108). Only one patient in the pregabalin group had a 
weight gain exceeding 7% of baseline weight (1). However, in a study concerning 
weight changes patterns for patients treated with pregabalin, Cabrera et al found 
that the majority of patients keep their weight within 7% of baseline weight but 
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those who gain more weight do so within 2 to 12 months of treatment (108). In the 
PACS study patients was only followed for 2 months which is a major limitation to 
the data on weight change (1).  
Only a minor and not statistically significant difference was seen between groups 
on the overall cognitive functioning (1). Mean BACS composite score was slightly 
increased for the placebo group, supposedly a “test-retest effect”, whereas no 
relevant change was seen for the pregabalin group (1). The difference between 
groups were not statistically significant and the results from Study I indicate that 
pregabalin does not cause significant impairment in cognitive functioning. 
 
EVALUATION OF HAM-A DATA AND CENTRALIZED RATING 
Max Hamilton recommended that a minimum of two raters was used to obtain 
acceptable precision in the assessment of symptom severity by the HAM-A scale 
(109). In the PACS study a method of centralized rating was used as a 
precautionary method of blinding (1, 2). Primary efficacy assessment was based on 
the combined ratings from all three central raters. As presented in Table 9, the 
interrater reliability between the three central raters was found acceptable 
supporting that the efficacy assessments were based on the mean rating scores of all 
three central raters (2). 
In Study II, a comparison between site-based ratings and centralized ratings was 
made to evaluate the differences in ratings (2). Interestingly, in the site-based 
ratings a statistically significant difference between groups was found on the HAM-
A14 but not on the HAM-A6 (2). Baseline values for both treatment groups were 
lower in the centralized ratings compared to the site-based ratings. If eligibility for 
participation had been assessed by centralized raters seven patients (13%) would 
not have been included in the study (2). Site-based ratings remained higher than 
centralized ratings, but the gap was reduced at the assessments after 4 and 8 weeks 
of treatment (2). As seen in Figure 2, this was most clearly seen in the pregabalin 
group on the HAM-A14. 
Statistical comparisons in efficacy trials can be made in several ways. In Study I 
and Study II, treatment effect was measured as change from baseline ratings to 
assessments after 4 and 8 weeks of treatment. This approach considers potential 
imbalances between treatment groups at baseline but does not correct for the 
tendency of “regression towards the mean” (110). Patients with a high score at 
baseline would generally have a higher chance of improvement. Only minor 
differences in baseline scores was seen in centralized ratings, but a relevant 
difference was seen in site-based ratings, mostly in the somatic items (2). This 
might be a part of the explanation for the higher effect size on the somatic anxiety 
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factor and the HAM-A14, seen in the site-based ratings and not in the centralized 
ratings. 
Generally, substantial loadings were seen on the somatic items of the HAM-A 
ratings. However, only minor change in these items was seen during treatment (1). 
This might indicate that pregabalin primarily is effective in treating the psychic 
component of anxiety in patients with schizophrenia. Another explanation might be 
adverse effects from concomitant treatment resulted in high loadings on the somatic 
items and therefore not treatable with pregabalin. 
Another factor to consider might be the different psychometric properties of the 
HAM-A6 compared to the HAM-A14. A recent study comparing the two versions of 
the Hamilton depression scale (HAM-D17 and HAM-D6) found a substantial 
difference between the scales, in their ability show drug superiority compared to 
placebo (111). Analysis performed in other studies have found the HAM-A14 to be 
multidimensional (43), and have found the HAM-A6 to have better statistical 
performance covering the core items for anxiety state severity (43, 74). However, 
rating scales may perform statistically different depending on the population it is 
applied to. No previous studies have tested the statistical properties of the HAM-A14 
and HAM-A6 in patients with schizophrenia and anxiety symptoms. In Study II, a 
Mokken Scale analysis was performed to measure the scalability of both scales (2). 
The HAM-A6 performed better statistically in all assessments (baseline, 4 weeks 
and 8 weeks) but the highest coefficient of homogeneity was found in the 8 weeks 
assessment (0.43 for the HAM-A6 and 0.37 for the HAM-A14) (2). A coefficient of 
homogeneity from 0.30 to 0.39 is according to Mokken only just acceptable, but 
levels of 0.40 or higher are quite acceptable (84). These findings indicate a better 
scalability of the HAM-A6 compared to the HAM-A14 and similar results have 
previously been reported by Bech (43). 
Blinding of treatment allocation in clinical trials is considered fundamental to avoid 
biased assessments. However, when raters hold knowledge about potential adverse 
effects experienced by study subjects, functional un-blinding may occur. In Study 
II the blinding success of the PACS study was evaluated using “exit-poll” data 
collected at the completion of the treatment period for each study participant (2). As 
shown in Table 7, site-based raters were highly able to “guess” treatment allocation 
for study subjects allocated to placebo. Study subjects were better to “guess” 
treatment allocation if they had been allocated to pregabalin treatment whereas 
study subjects guessed almost randomly if they had been allocated to placebo (2). 
The results concerning blinding of study subjects may both be indicative of 
participants experience of treatment effect or adverse effects, or may be a result of 
psychological factors like wishful thinking, i.e. patients want to think they were 
allocated to the active treatment (99). 
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The use of end-of-trial assessment of blinding success is a matter of debate (112) 
and results should be interpreted cautiously (99). However, the results may partly 
explain some of the differences seen between site-based ratings and the centralized 
ratings (2). The knowledge about adverse effects might have biased site-based 
raters distinction between adverse effects and somatic anxiety symptoms – resulting 
in a larger effect size on the somatic factor of the HAM-A in the site-based ratings 
and a statistically significant and clinically relevant difference between treatment 
groups was seen on the HAM-A14.  
 
CLINICAL CONSIDERATIONS TO USE OF PREGABALIN 
The suspected DDI interaction between pregabalin and the antipsychotic drug 
clozapine might impose a limitation to the use of pregabalin in patients with 
schizophrenia. Englisch and Gahr found a close temporal association between 
initiation of treatment with pregabalin and increase of plasma clozapine 
concentration (51, 53). The data from Study III provides the largest set of 
systematic observations addressing the suspected DDI between pregabalin and 
clozapine (3). Overall, the findings of Study III could not support the presence of 
such DDI as no increase in median p-clozapine in the pregabalin group was found 
and the largest individual increase was 15% - from baseline to 4 weeks assessment 
(3). However, studies addressing the intra-individual variation over time have found 
a significant variation of plasma clozapine on stable dosage of clozapine (113) and 
several factors have been found to influence the metabolism of clozapine (114). 
These may be static, like sex, or slowly changing factors like body weight and age, 
but also more rapidly changing factors like smoking habits or infections influence 
the metabolism of clozapine (114, 115). As shown in Figure 3, the largest 
individual increase was seen in the placebo group. 
An important limitation to the use of pregabalin in patients with schizophrenia is 
the abuse potential. Assessing abuse potential of a drug is a complex task and 
although preclinical and epidemiological studies directly have evaluated this topic 
the overall assessment must be summed up from circumstantial evidence evolved 
from both preclinical, clinical and epidemiological studies (4). Euphoria is a known 
adverse effect to the treatment with pregabalin (105).  
Based on the review of clinical trials reporting adverse effects euphoria was found 
to be a transient and dose-dependent adverse effect of pregabalin, occurring 
independent of indication and previous abuse of substances (4). The feeling of 
euphoria might explain why some patients tend to overdose pregabalin. As 
reviewed in Study IV, one to ten percent of patients treated with pregabalin 
experience euphoria as an adverse effect (4). In the PACS study, one patient in the 
pregabalin group (4%) experienced euphoria, starting at a dosage of 300 mg (1). 
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Although the feeling of euphoria seems to occur independently of previous 
substance abuse epidemiological studies have found that high use of pregabalin is 
more frequent among patients with previous substance abuse (4). These findings 
were supported by a recent Danish study, which also found an association between 
the use of antipsychotics with sedative effects and high use of pregabalin (116). 
In conclusion, the findings of Study IV indicate that pregabalin holds an important 
abuse potential which is important to consider when prescribing pregabalin, 
especially for patients with a known history of drug abuse (4). A detailed discussion 
of the findings of Study IV is presented in the appended Paper IV (4).  
 
LIMITATIONS AND GENERALIZABILITY 
The PACS study did not meet the required sample size and an important limitation 
to Study I and subsequently Study III is the low sample size (1, 3). Twenty-five 
patients were needed in each treatment group to detect a difference between 
treatment groups of at least 5 points on the total HAM-A14 score. The placebo group 
had a substantial reduction in HAM-A14 scores and one of the initial assumptions 
was that the placebo group would not change (1). Further, the variation in HAM-A 
scores within the groups were larger than assumed before trial startup (1).  
Another factor that may impose limitations to the results are the allowance of 
concomitant treatment during the PACS study (1). As shown in Table 3, a 
substantial number of patients received treatment with anxiolytic drugs, like 
antidepressants or hypnotics. However, as concomitant treatment was kept stable 
for at least four weeks before inclusion and through the study period delayed effects 
from other drugs are unlikely to have influenced the results (1). The concomitant 
use of other drugs, may however, in other ways impose a limitation to the results 
found in this study. Adverse effects may mimic anxiety symptoms, e.g. 
gastrointestinal adverse effects may be rated as gastrointestinal symptoms of 
anxiety, akathisia as tension. The presence of adverse effects from concomitant 
treatment may result in falsely high symptom loadings on the somatic anxiety factor 
of the HAM-A, which is not reponsive to treatment. 
The allowance of concomitant treatment, however, gives higher generalizability. 
The study sample included in the PACS study is considered close to the population 
where initiation of treatment with pregabalin would be considered. Many patients 
were in fact referred when their primary clinician considered treatment with 
pregabalin as treatment of severe anxiety symptoms. As the study was conducted in 
an everyday clinical setting,  the generalizability of the conclusions are well 
substantiated.  
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The HAM-A scale is not originally intended to measure anxiety in schizophrenia 
(74). However, the only rating scale designed especially for assessment of anxiety 
in schizophrenia, which is partly based on the HAM-A scale, needs further testing 
before the clinical and psychometric properties can be evaluated (71). In the PACS 
study, no sub diagnostic evaluation was made to further characterize anxiety of the 
included participants (1). It is therefore possible that effect of pregabalin is related 
to certain profiles of anxiety, and further studies are needed to investigate the nature 
of anxiety in schizophrenia.   
The most important limitation to the conclusions in Study III is the small sample 
size (3). The limited data material does not exclude the possibility that some 
patients may develop dramatic increases in plasma clozapine when pregabalin is 
added. The procedures related to the obtainment and handling of blood samples 
impose further limitations to Study III (3). The analyses performed in Study III 
was not originally included in the study design of the PACS study, and the 
collection of blood samples was not aimed for the investigation of plasma clozapine 
stability (3). The blood samples used cannot be considered as strict 12h values, as 
normally requested in assessments of plasma clozapine (117). Within subject 
variance in clozapine concentration may partly be explained by differences in 
sampling time between the three assessments (3). Further, blood samples were 
frozen and stored for later analyses. The storage of blood samples may alter the 
plasma concentration of clozapine over time. However, median number of days 
from obtaining blood samples to the analysis was not substantially different 
between groups (3).  
The findings in Study IV support the conclusions made in other studies addressing 
the abuse potential of pregabalin (118-120). The strength Study IV is the 
systematic search strategy and detailed review of the retrieved data. However, as 
discussed in Paper IV (4), bias may have occurred. Most preclinical data originated 
from studies conducted by the Marketing Authorization Holder (4). Unjustified 
omission of data from a self-administration study may distort the picture of the 
preclinical data as data concerning use of pregabalin in high doses were excluded 
(4). Publication bias may have occurred in relation to published case reports 
concerning abuse and misuse of pregabalin. Pregabalin was marketed in 2004 but 
concerns of the abuse potential was first mentioned in published literature several 
years later (121). Case reports concerning misuse and abuse of pregabalin were not 
published until 2010 (59, 122, 123). The concerns of abuse potential of pregabalin 
was solidified in the following years and may have increased the interest for 
pregabalin in abusive environments but also raised the focus on pregabalin as a 
drug with abuse potential. Another limitation to Study IV is the lack of consistency 
in the terminology used to describe misuse and abuse related events in the 
published literature (4).  
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8. CONCLUSIONS 
OVERALL FINDINGS OF THIS THESIS 
• Pregabalin was found to be effective, with a moderate effect size, as 
treatment of anxiety in patients with schizophrenia. The effect, however, 
was only seen on the psychic anxiety factor of the HAM-A14 and on the 
HAM-A6. No relevant difference was seen on the somatic anxiety factor. 
Pregabalin was generally well tolerated and most adverse effects were 
transient. However, weight gain may be a limiting factor in the use of 
pregabalin in patients with schizophrenia. 
• The method of centralized rating was found to be easy to apply and the 
overall experience is that this method is applicable in clinical trials using 
psychometric testing. 
• A high interrater agreement between centralized raters supporting the use 
of mean values in the efficacy assessments in the PACS study. The end-
trial assessment of blinding success found signs of functional un-blinding 
among site-raters. The Mokken Scale Analysis confirmed previous 
findings suggesting better scalability of the HAM-A6 than the HAM-A14. 
Centralized raters were better in separating the effect of pregabalin from 
placebo on the HAM-A6 compared to site-based raters. 
• In the observational subset of 8 patients from the PACS study, initiation of 
pregabalin did not increase the plasma concentration of clozapine. These 
results do not support the suspicion of an underlying drug-drug interaction 
between clozapine and pregabalin. 
• The review of existing literature indicates a relevant abuse potential of 
pregabalin, which may impose a general limitation to the use of 
pregabalin. Prescribers should pay attention of signs of abuse, especially in 
patients with a history of substance abuse. 
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